Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Alvogen Pine Brook LLC.) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis

NCT02995694 is registered in ClinicalTrials.gov with Alvogen Pine Brook LLC as lead sponsor.

NCT NCT02995694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02995694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Alvogen Pine Brook LLC.) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis
Lead sponsor
Alvogen Pine Brook LLC
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2016
Completion date
December 31, 2016
Enrollment
535 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrophic vaginitis